World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Molecular Biology 49 2627 2377 1283 1150 206 9696

Humam Kadara publications per year

The chart shows the history of publications by Humam Kadara between 2004 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Humam Kadara published across 23 years, from 2004 to 2026, averaging 22.3 papers a year. Output peaked at 224 publications in 2023. 27 of the 512 publications appeared in the last two years.

No. of publications
50 100 150 200
Bar chart. Horizontal axis: year, 2004 to 2026. Vertical axis: number of publications, 0 to 224. Peak 224 publications in 2023. 2004: 2 publications 2005: 0 publications 2006: 2 publications 2007: 2 publications 2008: 2 publications 2009: 3 publications 2010: 13 publications 2011: 10 publications 2012: 12 publications 2013: 5 publications 2014: 7 publications 2015: 9 publications 2016: 12 publications 2017: 22 publications 2018: 17 publications 2019: 13 publications 2020: 20 publications 2021: 35 publications 2022: 22 publications 2023: 224 publications 2024: 53 publications 2025: 25 publications 2026: 2 publications
2004 2026

512 publications in total across all disciplines

View publications per year as a table
Humam Kadara: publications per year, 2004 to 2026
Year Publications
2004 2
2005 0
2006 2
2007 2
2008 2
2009 3
2010 13
2011 10
2012 12
2013 5
2014 7
2015 9
2016 12
2017 22
2018 17
2019 13
2020 20
2021 35
2022 22
2023 224
2024 53
2025 25
2026 2
Total 512
Download as CSV

Humam Kadara publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Humam Kadara sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 53 bars. Horizontal axis: publications, 47–56 to 564+. Vertical axis: number of scientists, 0 to 177. Most scientists, 177, have 117–126 publications. The last bar groups every scientist with 564 publications or more. The highlighted bar, 197–206 publications, is where this scientist sits. 47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47–56 publications 564+

This scientist: 206 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

View publications distribution as a table
Number of Molecular Biology scientists by publication count, Research.com 2026 ranking edition. Based on 3,076 ranked scientists.
Publications Scientists This scientist
47–56 7
57–66 17
67–76 65
77–86 90
87–96 125
97–106 131
107–116 162
117–126 177
127–136 158
137–146 158
147–156 146
157–166 159
167–176 131
177–186 110
187–196 112
197–206 100 206
207–216 89
217–226 98
227–236 74
237–246 72
247–256 63
257–266 53
267–276 54
277–286 49
287–296 52
297–306 43
307–316 46
317–326 41
327–336 42
337–346 31
347–356 28
357–366 29
367–376 26
377–386 24
387–396 24
397–406 14
407–416 13
417–426 20
427–436 12
437–446 20
447–456 11
457–466 10
467–476 14
477–486 14
487–496 10
497–506 13
507–516 13
517–526 2
527–536 4
537–546 6
547–556 8
557–563 6
564+ 100
Download as CSV

Humam Kadara D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Humam Kadara sits on this spectrum.

No. of scientists
25 50 75 100 125
Bar chart with 54 bars. Horizontal axis: D-Index, 40–41 to 145+. Vertical axis: number of scientists, 0 to 131. Most scientists, 131, have 64–65 D-Index. The last bar groups every scientist with 145 D-Index or more. The highlighted bar, 48–49 D-Index, is where this scientist sits. 40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40–41 D-Index 145+

This scientist: 49 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

View D-Index distribution as a table
Number of Molecular Biology scientists by D-index, Research.com 2026 ranking edition. Based on 3,076 ranked scientists.
D-Index Scientists This scientist
40–41 36
42–43 101
44–45 115
46–47 121
48–49 118 49
50–51 130
52–53 106
54–55 116
56–57 113
58–59 129
60–61 120
62–63 105
64–65 131
66–67 95
68–69 97
70–71 106
72–73 83
74–75 89
76–77 77
78–79 70
80–81 73
82–83 60
84–85 48
86–87 45
88–89 50
90–91 31
92–93 51
94–95 43
96–97 38
98–99 39
100–101 41
102–103 29
104–105 33
106–107 35
108–109 20
110–111 38
112–113 19
114–115 28
116–117 13
118–119 23
120–121 16
122–123 15
124–125 11
126–127 21
128–129 7
130–131 13
132–133 14
134–135 17
136–137 9
138–139 8
140–141 16
142–143 7
144 7
145+ 100
Download as CSV

Overview

Humam Kadara is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions in oncology, molecular biology, and pulmonary and respiratory medicine. The scientist has published extensively in fields related to cancer research and immunology.

Key topics in their work include:

  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Single-cell and Spatial Transcriptomics
  • Cancer Cells and Metastasis
  • Immunotherapy and Immune Responses
  • Ferroptosis and Cancer Prognosis

Among their frequent co-authors are Ignacio I. Wistuba, Ansam Sinjab, Linghua Wang, Junya Fujimoto, and Tina Cascone, with collaboration counts ranging from 40 to 53 publications each.

Kadara has published numerous papers, including:

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance, 2023, Nature Medicine
  • Comprehensive T cell repertoire characterization of non-small cell lung cancer, 2020, Nature Communications
  • Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities, 2020, Cancers
  • 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy, 2021, Nature Communications

The scientist has been published frequently in leading research venues, including:

  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Regular and Young Investigator Award Abstracts
  • Cancer Discovery

Best Publications

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

    Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution

    Orit Rozenblatt-Rosen;Aviv Regev;Aviv Regev;Aviv Regev;Philipp Oberdoerffer;Tal Nawy

  • Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells

    Ashutosh K. Pathak;Manisha Bhutani;Asha S. Nair;Kwang Seok Ahn

  • Comprehensive T cell repertoire characterization of non-small cell lung cancer

    Alexandre Reuben;Jiexin Zhang;Shin Heng Chiou;Rachel M. Gittelman

  • IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras–Mutant Lung Cancer

    Mauricio S. Caetano;Huiyuan Zhang;Amber M. Cumpian;Lei Gong

  • Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

    H. Kadara;Murim Choi;Murim Choi;J. Zhang;E. R. Parra

  • ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer

    Mohamed Kabbout;Melinda M. Garcia;Junya Fujimoto;Diane D. Liu

  • Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma

    Tina Cascone;Matthew H. Herynk;Li Xu;Zhiqiang Du

  • EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

    Carmen Behrens;Luisa M. Solis;Heather Lin;Ping Yuan

  • Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities.

    Zeina Habli;Walid AlChamaa;Raya Saab;Humam Kadara

  • Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients

    Edwin R Parra;Carmen Behrens;Jaime Rodriguez-Canales;Heather Y Lin

  • High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation

    Maria Ines Nunez;Carmen Behrens;Denise M. Woods;Heather Lin

  • Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer

    Y. Kudo;Y. Kudo;C. Haymaker;J. Zhang;A. Reuben

  • Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung

    Ping Yuan;Humam Kadara;Carmen Behrens;Ximing Tang

  • 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.

    Guangchun Han;Guoliang Yang;Dapeng Hao;Yang Lu

  • Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome

    Luisa M. Solis;Carmen Behrens;M. Gabriela Raso;Heather Y. Lin

  • Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.

    Xin Hu;Junya Fujimoto;Lisha Ying;Junya Fukuoka

  • Knockout of the Tumor Suppressor Gene Gprc5a in Mice Leads to NF-κB Activation in Airway Epithelium and Promotes Lung Inflammation and Tumorigenesis

    Jiong Deng;Junya Fujimoto;Xiao Feng Ye;Tao Yan Men

  • Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.

    Smruthy Sivakumar;F. Anthony San Lucas;Tina L. McDowell;Wenhua Lang

Frequent Co-Authors

Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Carmen Behrens
Carmen Behrens The University of Texas MD Anderson Cancer Center
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Paul Scheet
Paul Scheet The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Don L. Gibbons
Don L. Gibbons The University of Texas MD Anderson Cancer Center
Cesar A. Moran
Cesar A. Moran The University of Texas MD Anderson Cancer Center
Avrum Spira
Avrum Spira Boston University
Jing Wang
Jing Wang The University of Texas MD Anderson Cancer Center
Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a future beyond molecular biology? Advancements in online education have opened diverse career pathways in related fields such as psychology, counseling, human services, and speech pathology.

If you are interested in supporting others’ mental health, exploring online master degree programs in counseling could be a great next step. For those passionate about research and therapy, clinical psychology online degree options prepare students for clinical and research roles in healthcare or academia.

Careers in social support and advocacy are also accessible via online human services degree programs, which typically offer flexible and accelerated study formats. Additionally, if you’re considering roles like speech-language pathology, it is possible to build on prior education—discover how can you become a speech pathologist with an education degree.

These accessible online degrees can open numerous doors in healthcare, research, and public service, making them valuable complements or alternatives to a background in molecular biology.

Best Scientists Citing Humam Kadara

Trending Scientists

Recently Published Articles